Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scientific, Not Legal, Developments Are Key To Generic Biologics – McClellan

Executive Summary

Generic drug firms can speed creation of a pathway for generic biologics by focusing on the science behind the products, former FDA commissioner Mark McClellan said

You may also be interested in...



McClellan Sees Roadblocks To Passing Biogenerics Bill This Year

Former FDA and CMS chief Mark McClellan sees a number of potential roadblocks to passing generic biologics legislation in 2007

McClellan Sees Roadblocks To Passing Biogenerics Bill This Year

Former FDA and CMS chief Mark McClellan sees a number of potential roadblocks to passing generic biologics legislation in 2007

Governors Take Aim At FDA For Not Releasing Follow-On Biologics Guidances

A bipartisan group of four governors are accusing FDA of violating the Administrative Procedure Act by not issuing guidance documents on therapeutically equivalent versions of insulin and human growth hormone products

Related Content

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel